
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$160.94
−$3.9145 · -2.37%
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Regular session
$161.01
−$3.8378 · -2.33%
Regular session · ET · Market data may be delayed.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Day range
Current $161.01
52-week range
Current $161.01
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
79
Undervalued
Sentiment
54
Mixed
Risk
50
Elevated Risk
Momentum
51
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Day range
Current $161.01
52-week range
Current $161.01
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8.25B USD | 8.28B USD | 8.12B USD | 7.74B USD | 5.48B USD |
| Cost of goods sold | 6.08B USD | 5.85B USD | 5.72B USD | 5.53B USD | 3.97B USD |
| Gross profit | 2.18B USD | 2.44B USD | 2.4B USD | 2.21B USD | 1.51B USD |
| Selling, general, and administrative | 780.14M USD | 728.35M USD | 776.36M USD | 778.75M USD | 585.33M USD |
| Operating expenses | 1.16B USD | 1.34B USD | 1.44B USD | 1.42B USD | 1.13B USD |
| Interest income | 7.11M USD | 8.61M USD | 5.01M USD | 2.35M USD | 574K USD |
| Interest expense | 188.11M USD | 237.24M USD | 336.7M USD | 229.73M USD | 182.42M USD |
| Depreciation and amortization | 383M USD | 488.5M USD | 585.95M USD | 614.73M USD | 360.33M USD |
| Operating income | 1.01B USD | 1.1B USD | 956.15M USD | 795.24M USD | 378.53M USD |
| Net income | 229.34M USD | 791.47M USD | 612.34M USD | 505.3M USD | 153.19M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$170.64
5.98% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 13, 2008 | 2:1 | — | — |
Stock split | Oct 24, 2006 | 2:1 | — | — |
Effective Aug 13, 2008
2:1
Effective Oct 24, 2006
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - US Small Cap Value ETFDFSV38.37M0.45%8.61B USD0.30%$40.125-0.78%
Dimensional - US Targeted Value ETFDFAT18.73M0.13%14.9B USD0.28%$71.17-0.91%
State Street SPDR Portfolio Developed World ex-US ETFSPDW16.02M0.04%42.37B USD0.03%$52.225-0.16%
Thrivent Small-Mid Cap Equity ETFTSME14.15M1.58%968.94M USD0.65%$48.12+0.48%
Distillate U.S. Fundamental Stability & Value ETFDSTL13.92M0.64%1.95B USD0.39%$67.70-2.37%
Dimensional - US Core Equity 2 ETFDFAC13.79M0.03%49.56B USD0.17%$45.495-0.49%
Brown Advisory Sustainable Value ETFBASV10.69M2.52%216.19M USD0.71%$31.54-1.14%
Vanguard Total World Stock ETFVT10.25M0.01%97.9B USD0.06%$161.31-0.26%
Dimensional - US Small Cap Value ETFDFSV
Dimensional - US Targeted Value ETFDFAT
State Street SPDR Portfolio Developed World ex-US ETFSPDW
Thrivent Small-Mid Cap Equity ETFTSME
Distillate U.S. Fundamental Stability & Value ETFDSTL
Dimensional - US Core Equity 2 ETFDFAC
Brown Advisory Sustainable Value ETFBASV
Vanguard Total World Stock ETFVTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.